Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675247 | 0.95 | HTR2C (0.56) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL2675996 | 0.90 | OPRM1 (0.62) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL21307175 | 0.86 | HTR2C (0.60) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL21307179 | 0.86 | HTR2C (0.60) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL8275622 | 0.84 | OPRM1 (0.54) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL3870991 | 0.83 | OPRM1 (0.60) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL5871428 | 0.82 | HTR2C (0.83) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL16948341 | 0.81 | HTR2C (0.59) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL10652419 | 0.81 | HTR2C (0.71) | HTR2CHTR2BOPRM1OPRD1OPRK1 | |
| SCHEMBL12638317 | 0.81 | HTR2C (0.71) | HTR2CHTR2BOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435960-B1 | IMIDAZO[4,3-E]-1,2,4-TRIAZOLO[1,5-C]PYRIMIDINES AS ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| EP-2295047-A2 | Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders | Schering Corporation (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2269596-A2 | Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders | Schering Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1578409-B1 | USE OF ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATMENT OR PREVENTION OF EXTRA-PYRAMIDAL SYNDROME | SCHERING CORP (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-7414058-B2 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007047293-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007038212-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2004-07-15 | — | — | US | disclosed |
| WO-2003032996-A1 | IMIDAZO (4,3-E)-1,2,4-TRIAZOLO(1,5-C) PYRIMIDINES AS ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | HTR2C 1041/4885HTR2B 1332/4885OPRM1 779/4885 |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, ADORA2B | HTR2C 21/4885HTR2B 11/4885OPRM1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.